trial protocol

  1. SNT Gatchaman

    Protocol An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID, 2026, Neilens, Faghy et al.

    An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID BACKGROUND Long COVID (LC) affects around two million people in the UK and over 65 million people globally. Antiviral medications have shown positive effects in reducing the risk of progression to severe...
  2. Wyva

    Metaresearch on patient-reported outcomes in trial protocols and results publications suggested large outcome reporting bias, 2025, Heravi, Busse et

    Ala Taji Heravi ∙ Dmitry Gryaznov ∙ Jason W. Busse ∙ Christof Manuel Schönenberger ∙ Belinda von Niederhäuserne ∙ Lena Hausheer ∙ Manuela Covino ∙ Johannes M. Schwenke ∙ Selina Epp ∙ Alexandra Griessbach ∙ Malena Chiaborelli ∙ Arnav Agarwal ∙ Szimonetta Lohner ∙ Julian Hirt ∙ Stefan...
  3. SNT Gatchaman

    [Preprint/Protocol] Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design, 2023, Gross et al.

    Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design Importance: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or “Long COVID”) in children and young adults remain unknown...
  4. SNT Gatchaman

    [Protocol] Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized Controlled Trial of Ivabradine for POTS (COVIVA Study)

    Comparative Cohort Study of Post-Acute Covid-19 Infection with a Nested, Randomized Controlled Trial of Ivabradine for Those With Postural Orthostatic Tachycardia Syndrome (The COVIVA Study) David Saunders; Thomas B Arnold; Jason M Lavendar; Daoqin Bi; Karl Alcover; Lydia D Hellwig; Sahar T...
Back
Top Bottom